Protara Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Protara Therapeutics, Inc. carries a market capitalization of 157.83M, placing it among publicly traded companies globally. Its enterprise value stands at 112.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 157.83M |
| Enterprise Value | 112.30M |
Share Statistics
Protara Therapeutics, Inc. currently has 55.06M shares outstanding.
| Shares Outstanding | 55.06M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.77 |
| P/TBV Ratio | 1.40 |
| P/FCF Ratio | -3.89 |
| P/OCF Ratio | -3.89 |
Financial Position
Protara Therapeutics, Inc. maintains a current ratio of 15.69, meaning it holds 15.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 15.69 |
| Quick Ratio | 15.39 |
| Debt / Equity | 1.69 |
| Debt / EBITDA | -0.04 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -35.12 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Protara Therapeutics, Inc.'s stock has gained approximately 19.59064% over the past 52 weeks. The 50-day moving average sits at 4.33, while the 200-day moving average is 5.33.
| Beta (5Y) | N/A |
| 52-Week Price Change | 19.59064% |
| 50-Day Moving Average | 4.33 |
| 200-Day Moving Average | 5.33 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -69.68M, while operating income came in at -70.05M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -70.05M |
| Pretax Income | -63.31M |
| Net Income | -63.31M |
| EBITDA | -69.68M |
| EBIT | -70.05M |
| Earnings Per Share (EPS) | -1.35 |
Balance Sheet
Protara Therapeutics, Inc. holds 135.79M in cash and equivalents against 3.06M in total debt, resulting in a net debt position of -14.74M. Total book value stands at -320.15M, with working capital of 131.08M providing operational flexibility.
| Cash & Cash Equivalents | 135.79M |
| Total Debt | 3.06M |
| Net Debt | -14.74M |
| Equity (Book Value) | -320.15M |
| Book Value Per Share | -6.81 |
| Working Capital | 131.08M |
Cash Flow
Protara Therapeutics, Inc. produced -62.99M in operating cash flow over the past twelve months. After subtracting -50,000.00 in capital expenditures, free cash flow totaled -63.04M - equivalent to -1.34 per share.
| Operating Cash Flow | -62.99M |
| Capital Expenditures | -50,000.00 |
| Free Cash Flow | -63.04M |
| FCF Per Share | -1.34 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -33.52 |
| FCF Yield | -25.69 |
Stock Splits
Protara Therapeutics, Inc.'s most recent stock split took place on January 10, 2020 with a 40:1 split ratio.
| Last Split Date | 1/10/2020 |
| Split Ratio | 40:1 |
Scores
Protara Therapeutics, Inc. posts an Altman Z-Score of 10.91, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 10.91 |